# Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal

> **NCT03541356** · PHASE2 · COMPLETED · sponsor: **Impel Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **COMBINATION_PRODUCT:** Placebo
- **COMBINATION_PRODUCT:** L-dopa 35 mg
- **COMBINATION_PRODUCT:** L-dopa 70mg
- **COMBINATION_PRODUCT:** L-dopa 140 mg
- **COMBINATION_PRODUCT:** L-dopa 70mg/carbidopa 7mg

## Key facts

- **NCT ID:** NCT03541356
- **Lead sponsor:** Impel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-08
- **Primary completion:** 2019-06-11
- **Final completion:** 2019-06-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03541356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03541356, "Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03541356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*